ADAP - Earnings call transcript Q2 2021 | Adaptimmune Therapeutics plc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and thank you for standing by. Welcome to the Adaptimmune Second Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. to conference like Miller, to now Relations. Investor will turn over the Juli I ahead. go Please

Juli Miller

with forward-looking for those welcome Officer the prepared and factors, our and outlined second filings and SEC. review projections to press Executive call, financial me latest our conference several our be anticipate we could available quarter results the our this making our is differ Rawcliffe, of release, Please due that, for as update. with this Hello, business Adaptimmune's results XXXX including of Q&A. to over call call Rawcliffe. management the to the will Adrian call during portion Ad? Chief from members afternoon's With in other turn actual statements Adrian I'll to discuss materially team

Adrian Rawcliffe

and Thanks, for everyone Juli, us. joining thanks

the each one, our start a set are this as beginning for about of I in at year, ESMO to our QX milestones XXXX identified I'm at ILCA; out data next bit last positioned afami-cel our three, anticipated. an from to SPEARHEAD-X on clinical that, full these pleased we turn. milestones deliver in of ESMO. two From pivotal program say perspective, from delivered next strategy. the present MAGE-AX year, say trial our data data data initial targeting to with X-X-X-X ILCA at to So SURPASS at to years. QX, with of with present at at these from a and set ASCO, first next-gen trial with Two, five and excellent on we our present in to trial to afami-cel that we the CTOS. want a data strategy deliver in And and little milestones we follow AFP ASCO, the these the were:

presented we a we can ASCO. June, QX. pivotal SPEARHEAD-X trial our the at busy press In initial see from data release, you had from As

this rate working With rate data XX%, file this the potential control and next first very CTOS disease We of later demonstrates element response and initial for the has people these from sarcoma XX%, encouraging that to hard and afami-cel data our to product trial plan to life-changing an of approximately overall achieve synovial we're with MRCLS. year market our approximately have MAGE-AX. And on year. update of targeting BLA X-X-X-X strategy a at the durability,

vector diagnostic; commercial preparing for our for working for with lentiviral well support as launch developing in-house commercial our Miltenyi Agilent key We supply, afami-cel. a delivery for are successful as to companion industry leaders: capabilities

data from had Phase in will the trial. who've the second Sangro September milestones we the our and Dr. third and have patients, least on to scan. on present ESMO, are He update who present expansion, AFP respectively. and and been on treated X At in Cohort level of year, ILCA, SURPASS this will programs AFP For QX, ILCA at a clinical post-baseline XX data one track Bruno at on X our Xth,

full forward. targeting program a our release program update this we data regarding At MAGE-AX. around and press going with next-gen from issue will update these We trial SURPASS presented the ESMO, will

EGJ six two as as confirmed that data with patients we cancer, and neck well cancers. head remember Fitzy escalation in trial, responses reductions patients other esophageal, three ovarian this reported at and and cohort You'll year, from tumor with the last of EGJ and in with dose patients

enrollment first QX in call well. the half in I very of May, said in in has trial XXXX this As the gone

Based to have of ovarian very this wide sharing we to treated in tumors, this scan. MAGE-AX anti-tumor range looking we least list much a will presentations, targeted And responses trial activity indications and we SURPASS and development in poster on of cut are provide lung, available this of these patients the for data MAGE-AX the trial post-baseline cancers, subsequently The gastroesophageal will the the update was treated As ovarian the be focus program, we was to patients update initially future updates focus therapy. for cancer release but issue the an and at emerging press add forward data bladder, on patients planned seen and XX the ESMO SURPASS Again, full with and other on with neck in one this at expressing September cancer our the data back of therapies several a have in on online ESMO. we trial, Couple indications. full previously. XXth. as will recruiting XX head of amended of where

So going gastroesophageal forward, enroll trial SURPASS with continue ovarian neck, bladder, will to and cancer. the lung, patients and head

most trial, account EGJ a cancers QX. We've is our patients this population targeting designed from for in a setting SURPASS-X to the that evolving Phase standard the benefit to esophageal type with patient care planned and this which as initiate of track on In is with likely addition, is to identify MAGE-AX the and for next-gen X therapy. trial in protocol of product

X-X-X-X goal committed We an next the MAGE-AX in having phase years. marketed five more are with indications identify of for to product development late additional the

our that, cell every translational as turn closer And to our it us with I'd pipeline, preclinical well to that our over and program mainstream. to products our curative operator therapy both for including the day questions. allogeneic are move goal learnings, data, like industry-leading clinical as Our of

Operator

ROTH Capital. Instructions] question Butler our first [Operator And Tony comes from with

Your line is open.

Tony Butler

validation. are taking you Agilent. And for development diagnostic you're with There the clear Adrian, companion two that I much am going to assuming see with questions. very mentioned Thanks two parts. the one

esophageal to is, - So can delay, that of I And you one importantly, Astellas also do to of or to if that And you and you of joint number ownership validated Question two that of would the the use taken would cancer if around the have And cause how may program. wondered, that an I particular b, or any you question that to venture I will far second had delay part And you some programs the you in speak a was provide provide taken will program filing will EGJ. you see BLA of around on that information development want that, but recall one question, cause this need Astellas? in, based fine, the if HiT the it you it you. to longer in reveal the program think with believe SURPASS-X, is both? Thank the don't patients in in the FDA? any SPEARHEAD-X? diagnostic

Adrian Rawcliffe

Thanks, Tony.

any not the pathway that to I file the any details there development the SURPASS-X provided we have basis companion we on - be the So, on diagnostic. of BLA question don't Could trial? anticipate won't for to the on you that. the can delay delay repeat confirm

Tony Butler

in rolling, going going companion that SURPASS-X even therefore diagnostic said trial QX? you're though use you and so Yes, that to be be to in it's in actually Thanks. the may trial, delayed the somewhat

Adrian Rawcliffe

comment to and the so that diagnostic on delayed no. be that going programs. to Helen of Yes, to don't With trial, is ask enrolling. I'm answer in will We're Astellas the status we collaboration, those the respect using in that, anticipate not that

Helen Tayton-Martin

Adrian. Thanks,

as second repeat I and independent one on we back Tony. co-developing are get program, question, name to first Mesothelin target HiT, think HLA the of were a that one double I you, it one we the you our just Can or for for thanks the So checking to TCRs there.

The but is is, is won't that foreseeable, the be question? second has named been one selected, and not named,

Tony Butler

take you, issue thank and decided wings to along the Helen since as is, It progressed how their was has well? program that under that they have far

Helen Tayton-Martin

liberty the that anticipated target. I would moving to in selecting how say but far is it's get it the along for exactly timelines we progressed,

think but the finding not from I basically, So, early, program. Mesothelin far that

Operator

next Cowen Our Marc comes from Frahm Company. question and with

line open. Your is

Marc Frahm

patients last patients to you of update? is as one bit questions that your have based little that, Maybe Thanks you've getting I update, ovarian congrats subsequent comment a shrinkage for within that a additional that to that seen really about is because my is that just these tumor taking it and be or for think in you tumors, on in clear, presentation. on of ovarian on patient and of it had some in happened Adrian, focus ready adding more SURPASS, all the had

Adrian Rawcliffe

on release. of data We the the are that to data comment going is trial ESMO pending any in SURPASS the

question data that will look all answered be think much have and when I of there. we can amount better the discussion same that at

Marc Frahm

us similar there, but a And of types quite a flavor were answer can Okay. may historically case? but of that patient patient kind high gave that kind you be give proof-of-concept about are give numbers, any going threshold you - you of tumors our of - of get to be spread in of flavor that thinking get answer. kind futility, to for can the But in kind of same starting talked tumor to should that if that type or you've these useful about establishing we single-digit here,

Adrian Rawcliffe

correct. You're

to persistence going my on do this. same from the get but You're I with answer previous question, the as

ESMO, think at and it guided there the going everybody we it best, month haven't an can to point. data We it's important put we're when from at not it's and perspective a away I can out set guide, at about talk that we only look

Marc Frahm

already just patients plus enrolled of the enroll you trial Okay. plan response some rate second patients, do continuing of cohort And to to the BLA, of that Will including we've the turning have then patients seen couple have first who expect these into the filing that you're cohort to data, the the or cohort? incremental complete second filing are maybe a SPEARHEAD-X. in

Elliot Norry

is X. Hi, the the based in plan it's BLA Yes. Marc, Cohort on data Elliot. The file to

Operator

Our Smith next Guggenheim. with question Michael from comes

open. Your line is

Kelsey Goodwin

from just there commercial we This Michael. why quick stand prep second maybe the one, Could sub-study And with some little And just stopped? it is press ones. on readiness? you had of radiation the it you. officially two you launch on and was in where I a bit color that color just Kelsey release then me. the from the provide Thank that's on saw closed,

Adrian Rawcliffe

do are pick sub-study. touch to commercial with I Elliott readiness where just Kelsey. will you ask Thanks, and on to And we up the want prep? on radiation Helen,

Helen Tayton-Martin

we're the commercial beginning I'll around things broad kick obviously the customer for that for the in facing quite to attention time. turn deeper marketing, good had and now one. been to internal shape. planning on key off we're and this dig to outward We've into I with the answer mean sure. access, reasonably also Yes, I We've focus planning our roles. market some think

on beginning level So John, as imagine of closely and different cetera, And for materials, that's et and then map the delivery do and working to comment feedback of ready pathways very side. sort kinds rolls and prep, can the we getting to out on of manufacturing on of operations, all place then very that you products would quite KOLs, technical side. going what with easily in our on to of complement our operations clinical for commercial kind

So we're with calls, we'll more I in sure, due I'm how - but about pleased at it's tracking. we're say this think yes, stage,

Adrian Rawcliffe

want John, the CMC to do on pick this? aspects you of up

John Lunger

come commercial the here that trials, using then we've we before our in said loans We've Sure. and facility need will launch. that the clinical Philadelphia we out that had for been that of for same capacity the

the supply-wise those in which BLA the work well. for through we're is proceeding and obviously of shape, things, So you of type and we're need process that to filing, activities good then prepare all going the characterization

Adrian Rawcliffe

on Elliot, touch to radiation do sub-study? you want

Elliot Norry

Yes, sure.

it enrollment we as challenging center, into on also And addition the it to very a for enrollment end based look with Phase relates was had a sufficient affected of really afami-cel study. open. to was of part decided remaining And enrollment provide standpoint back organized, the scenario multiple cell And differentiating sub-study answers really COVID really we centers. - well, the trial pandemic. presented unlikely therapy. was radiation really the the as an it to reasons. how center with significantly from been the This when to dose was that expanding X, So radiation for multi-tumor by at study only the single and single in The other design sub-study low

at there alpha that while really idea we'll focus that promise program low This types MAGE-AX using of dose The time, the it good enroll still, So, to a put into think sense. to T-cell us sense for to trafficking, of CDX reintroduce radiation if is later to same the study sort retain improve option be is I makes and scientific for enroll. tumor continue to not did to those expressing really continue real SURPASS. are make and the to

Operator

comes question SVB Jonathan next with Our from Leerink. Chang

Your line is open.

Jonathan Chang

into program the as go/no-go you next-gen stage different later indications X the see SURPASS advancing the do bar study? what question, for beyond development First MAGE-AX the for Phase

Adrian Rawcliffe

I'll at that. stab take So a maybe

tumor get speculation think I about the don't I And so - individual into want - to types.

just we'll ESMO. that to the I look in late cell give would efficacy everybody the what previously benefit as be consistently of very would this we've let data I Phase for in those in we've with itself like. months or see. trial I'd said to think looking take But that responding refer that think, about out with stage think of such probably that we're six speak patients had discussions studying populations patients XX And X I three the we're ballpark to therapy,

ESMO and the but from a forward types, that data and little obviously settings vary does we discuss doing to before that depending to understand think and - tumor onwards. so more Now, need on bit individual look I we can

Jonathan Chang

What a indication similar a to the picking the a bar as you in go/no-go in maybe do lane. focus be same ongoing see SURPASS study? And particular the for indication question

Adrian Rawcliffe

of that a as have selected Well, trial on behind recruited to Phase ESMO. an of therapies obviously, not And earlier, and that, we lung, really focusing down the trial previously. responses indications we to ovarian. or talk the about of patients all have substantial MAGE-AX, bladder activity. and neck treated commented that that in didn't indications number activity analysis We make MAGE-AX bit the any And to get those a And afami-cel were a XX seen manageable indications gastroesophageal, I may it but then down get was you I'm we'll portions simpler. the a urothelial was we could sort we of recall. there, of we very bladder, you patients numbers confirmed the And when might from very or more a in that dose the SURPASS recall one also go In some either But is selected - way were bit we head generally to rationale non-sarcoma had both to to that that indications escalation four of development targeting the was comment the where of focused more we study ago, then we the responses express case X with we going it anti-tumor cancer. for putting time indications seen significant anti-tumor the patient down something and that had that decisions. where more bit try routinely had

Operator

Our next question comes from Mara Goldstein with Mizuho.

open. is Your line

Mara Goldstein

Hi, it's Goldstein. Mara

to speak about in to you what alluded Just SURPASS-X, I'm that questions supply to sort spoke time? few a prepared management. couple cell of to to doing? of modifications the you you the some And heard if your and companies around a constraints. space - this from conform then you a you're care. we've it relates could on supply point just standard guys is, bit that also wondering Maybe of to kind sort comments I'm as around just curious, making you can speak of evolving hey, within vector therapy second to little in And And of at specifically

Adrian Rawcliffe

Mara. Certainly, thanks,

I'm SURPASS-X around going to supply. standard to and the up about strategy So pick of John our study, evolution on Elliott to ask there. back the talk And ask discussion then care to I'll the

Mara Goldstein

you. Thank

Elliot Norry

hi, Mara. Yes

advancement are the those other from play In by really cancers in it it two followed opens that scenarios of a also as but commonly treatments line. they gastroesophageal those is of don't approach many those compressing this rate PD-X mean, response although now first with help and being need type, those being in really patients. They're drugs way patients most some to just chemotherapy - does combination, with in first-line for first-line up patients space that then There for Just briefly, tumor in, then all, specific and the chemotherapy are inhibitor. care receive standard a with tremendous third-line That in I drugs into patients things. very care standard has and being settings, long there there evolved to open therapy second-line an this but really first for still be better response approach, the the comment improves still the is progress treatments. go quite fairly with patients, to the that, and two that of disease receive, the unmet first diseases. a combination duration used which of that those said, don't then population - inhibitor, for devastating progress still PD-X

Mara Goldstein

essentially you'll second-line be expect what will a I'm then therapy of make that to modification, is So closer to sort move to understanding?

Elliot Norry

for does line second beyond. in be study used to allow The the drug

Mara Goldstein

Okay.

Elliot Norry

Behind respect changes most we've we've in whatnot that's to patient program, X what combination change. with based the significant made chemotherapy, some on but Phase and other the selection learned

Mara Goldstein

you. Thank right. all Okay

John Lunger

Yes back pursue made through used the vector vector supply an we've for a we and recall Miltenyi Miltenyi our that Ad SPEARHEAD XX with could trial us which external strategy main the probably and commercial was work had partner on with One vector, that elements. for the mentioned in and XXXX, decision trials. work other earlier, to

capability. also So we commercial. secondly we'll use material into going that's the the decided that to develop internal But

in So new from our the gene done supplying facilities. other a produced we U.K. with our cell material that and therapy It's internally have trials and Catapult we're center

us, sources one kind we're and So, plan the external. to internal of executed vector on of have to available one two

Operator

closing back the Adrian like there it questions to Rawcliffe Thank you. to I'd And in for remarks. queue. are no turn other

Adrian Rawcliffe

that, With forward the Thanks the September your lot. We on continued up-to-date updating a keeping Thank progress. call. in data you, everyone look everyone to we'll continued and for close support the company. for your and with questions you

Operator

call. you today's Thank conference concludes for participating. This

great disconnect. a have now You day. Everyone may

Adaptimmune Therapeutics (ADAP) 10 Aug 212021 Q2 Earnings call transcript